| Sustained effect of LACTIN-V (Lactobacillus crispatus CTV-05) on genital immunology following standard bacterial vaginosis treatment: results from a randomised, placebo … E Armstrong, A Hemmerling, S Miller, KE Burke, SJ Newmann, SR Morris, ... The Lancet Microbe 3 (6), e435-e442, 2022 | 37 | 2022 |
| Metronidazole treatment rapidly reduces genital inflammation through effects on bacterial vaginosis–associated bacteria rather than lactobacilli E Armstrong, A Hemmerling, S Miller, KE Burke, SJ Newmann, SR Morris, ... The Journal of clinical investigation 132 (6), 2022 | 35 | 2022 |
| Beyond bacterial vaginosis: vaginal lactobacilli and HIV risk E Armstrong, R Kaul Microbiome 9 (1), 239, 2021 | 24 | 2021 |
| Optimizing the vaginal microbiome as a potential strategy to reduce heterosexual HIV transmission E Armstrong, R Kaul, CR Cohen Journal of Internal Medicine 293 (4), 433-444, 2023 | 8 | 2023 |
| Travelling for sex, attending gay-specific venues, and HIV-related sexual risk among men who have sex with men in Ontario, Canada E Armstrong, T Coleman, NM Lewis, S Coulombe, CL Wilson, ... The Canadian Journal of Human Sexuality 29 (3), 380-391, 2020 | 8 | 2020 |
| Soluble E‐cadherin: A marker of genital epithelial disruption R Liu, E Armstrong, S Constable, LB Buchanan, A Mohammadi, ... American Journal of Reproductive Immunology 89 (3), e13674, 2023 | 7 | 2023 |
| Treatment success following standard antibiotic treatment for bacterial vaginosis is not associated with pretreatment genital immune or microbial parameters E Armstrong, A Hemmerling, V Joag, S Huibner, M Kulikova, E Crawford, ... Open forum infectious diseases 10 (1), ofad007, 2023 | 5 | 2023 |
| Out of sight, out of mind: mechanisms of social choice in fish R Ayoub, E Armstrong, NY Miller Animal behaviour 155, 163-169, 2019 | 5 | 2019 |
| Response to antibiotic treatment of bacterial vaginosis predicts the effectiveness of LACTIN-V (Lactobacillus crispatus CTV-05) in the prevention of recurrent disease A Hemmerling, MR Wierzbicki, E Armstrong, CR Cohen Sexually Transmitted Diseases 51 (6), 437-440, 2024 | 1 | 2024 |
| Response to antibiotic treatment of bacterial vaginosis predicts the effectiveness of LACTIN-V (Lactobacillus crispatus CTV-05) in the prevention of recurrent disease A Hemmerling, MR Wierzbicki, E Armstrong, CR Cohen medRxiv, 2023.10. 19.23297283, 2023 | 1 | 2023 |
| Impact of LACTIN-V (Lactobacillus crispatus CTV-05) on genital immunology following standard bacterial vaginosis treatment: Results from a randomized placebo-controlled trial. E Armstrong, A Hemmerling, S Miller, K Burke, S Newmann, S Morris, ... Journal of the International AIDS Society 24 (S1), 46-47, 2021 | 1 | 2021 |
| Vaginal fungi are associated with treatment-induced shifts in the vaginal microbiota and with a distinct genital immune profile E Armstrong, A Hemmerling, S Miller, S Huibner, M Kulikova, R Liu, ... Microbiology Spectrum, e03501-23, 2024 | | 2024 |
| Vaginal Lactobacillus crispatus persistence following application of a live biotherapeutic product: colonization phenotypes and genital immune impact E Armstrong, A Hemmerling, S Miller, S Huibner, M Kulikova, E Crawford, ... Microbiome 12 (1), 110, 2024 | | 2024 |
| O03. 2 The short-term immune impact of bacterial vaginosis treatment is unrelated to Lactobacillus spp. abundance E Armstrong, A Hemmerling, S Miller, K Burke, S Newmann, S Morris, ... Sexually Transmitted Infections 97 (Suppl 1), A20-A21, 2021 | | 2021 |
Rupert KaulClinician scientist, University of Toronto在 utoronto.ca 的电子邮件经过验证
